Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Three big pharma VC arms bet on FoRx’s novel cancer approach

The VC wings of three big pharma companies – Novartis, Pfizer and the Merck group – have all continued their support for Swiss oncology biotech FoRx in its seed round. What makes FoRx so promising in the competitive, crowded oncology space?

Close
Close
Close

Go Top